ReferencesPackage Insert: http://www.gene.com/gene/products/information/perjeta/pdf/perjeta_prescribing.pdf
1. Joensuu H, Escalating and de-escalating treatment in HER2-positive early breast cancer. Cancer Treatment Reviews 52 (2017) 1 – 11. http://www.cancertreatmentreviews.com/article/S0305-7372(16)30118-9/pdf
2. Maly, J. J. and Macrae ER. Pertuzumab in combination with Trastuzumab and chemotherapy treatment of HER2-positive metastatic breast cancer: safety, efficacy, and progression free survival. Breast Cancer: Basic and Clinical Research 2014:8, 81-88 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022699/
3. Singh JC., Jhaveri K. and Esteva FJ. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. British Journal of Cancer. 2014 June; 111, 1888-1898. http://www.nature.com/bjc/journal/v111/n10/full/bjc2014388a.html
4. Durkee BY., Qian Y., Pollom EL., et al. Cost-effectiveness of Pertuzumab in human epidermal growth factor receptor 2 – positive metastatic breast cancer. Journal of Clinical Oncology. 2015 September 8; 33, 1-12. http://jco.ascopubs.org/content/early/2015/09/03/JCO.2015.62.9105.full
5. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12; 366(2):109-119.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22149875
6. Keating GM. Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer. Drugs. 2012 Feb 12; 72(3):353-360.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22316351
7. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012 Jan; 9(1):16-32.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22124364
8. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997 Aug; 15(8):2894-2904.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9256133
9. Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol. 2000 Oct; 27(5 Suppl 9):13-19.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11049052
10. Kawajiri H1, Takashima T, Kashiwagi S, Noda S, Onoda N, Hirakawa K. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Expert Rev Anticancer Ther. 2015 Jan; 15(1):17-26. http://www.ncbi.nlm.nih.gov/pubmed/25494663
11. Swain SM, Baselga J, Kim S-B, Ro J, Semiglazov V et al. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. N Engl J Med 2015; 372:724-734. http://www.nejm.org/doi/full/10.1056/NEJMoa1413513